Goldman Sachs Resumes Biogen (BIIB) at Conviction Buy on Upcoming Drug Launches
Tweet Send to a FriendGet Alerts BIIB Hot Sheet
Price: $226.85 -0.5%
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade BIIB Now!
Goldman Sachs resumes coverage on Biogen (NASDAQ: BIIB) with a Conviction Buy List rating and $178 price target.
"Biogen is on the verge of launching two new drugs, BG-12 for multiple sclerosis (MS) and rF8/9 for hemophilia, and has a robust mid to late stage pipeline," the firm comments.
Goldman expects the launch trajectory of Biogen's new oral MS drug, BG-12, in 2Q13 to be steeper than the Street expects by the results of their physician survey.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $152.35 yesterday, with a 52 week range of $109.05-$157.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"Biogen is on the verge of launching two new drugs, BG-12 for multiple sclerosis (MS) and rF8/9 for hemophilia, and has a robust mid to late stage pipeline," the firm comments.
Goldman expects the launch trajectory of Biogen's new oral MS drug, BG-12, in 2Q13 to be steeper than the Street expects by the results of their physician survey.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $152.35 yesterday, with a 52 week range of $109.05-$157.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Describes Cisco (CSCO) Q3 as 'Breakout Performance'
- Barclays Starts AT&T (T) at Equalweight
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman Sachs Conviction Buy List, Goldman Sachs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
